8:30 - 8:45 Welcome Address
  Ambassador of France, HR Pierre Vimont
8:45 - 9:00 Welcome and Introductions

Prof. J.H Growdon, Clinical Core Co-Leader and Founding Director at Massachusetts Alzheimer's Disease Research Center & Director, Memory and Movement Disorders Units at Massachusetts General Hospital & Professor of Neurology at Harvard Medical School

Prof. P. Amouyel, CEO French National Foundation on AD, General Director of the Pasteur Institute of Lille and Professor of Epidemiology and Public Health at the University Hospital of Lille in France.

9am-9.30am Session I : New Genes for New Clues
  Prof. Philippe Amouyel
Topic: European Alzheimer's Disease Initiative Consortium (EADI), a European GWAS

Dr. Sudha Seshadri
Topic: Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE) and Alzheimer’s disease
9.30-10am Panel discussion
10-10:30am Session II : New Molecular Vision of AD
  Prof. Bradley Hyman
Topic: soluble Aß and synaptic damage in AD

Dr. Frederic Checler
Topic: Aß and tau neurotoxicity
10.30–11am Panel discussion
11-11.30.am Coffee break
11.30-12:15 Session III : Prodromal AD - New Diagnostic Challenges
Prof. Guy McKhann
Topic: National Institute of Ageing update on AD diagnostic criteria

Prof. Bruno Dubois
Topic: Revised diagnostic guidelines for the MCI-AD continuum

Dr. Deborah Blacker
Topic: DSM-V criteria for dementia and AD
12:15-12:45 pm Panel discussion
12:45-2:00 pm Lunch
2:00 – 2:30 pm Session IV : New ways to Image the AD brain
  Prof. Chester Mathis
Topic: Brain amyloid imaging and its impact on AD research

Dr. Stephane Lehericy
Topic: MRI techniques to diagnose and chart the course of AD
2.30 – 3:00 pm Panel discussion
3:00 – 3:30 pm Coffee break
3:30 – 4:00 pm Session V : New Therapeutics for AD
  Dr. Reisa Sperling
Topic: Incorporating biomarkers (CSF, neuroimaging) into clinical AD trials

Prof. Jean-Marc Orgogozo
Topic: Perspectives for developing novel symptomatic and neuroprotective drugs for AD
4:00 – 4:30 pm Panel discussion with Speakers
  Session VI : Biopharmaceutical perspectives & the drug market
4:30-5:00 pm Dr. Dana Hilt, Chief Medical Officer of Envivo at Envivo Pharmaceutical
Topic: “Symptomatic Versus Disease Modification Treatments for Alzheimer’s Disease from the Perspective of a CNS Biotech Company”

French biopharmaceutical company: Subject to minor changes
5:00 pm Concluding remarks: Profs. Growdon and Amouyel